Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging compound targets Hard-to-Spot cancers

NCT ID NCT07707531

Recruiting now Diagnosis Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a radioactive compound called IR199 in people with gastric or pancreatic cancer that has a specific marker, Claudin 18.2. The goal is to see how the compound spreads through the body and how much radiation reaches tumors and healthy organs. Ten participants receive a single dose, and doctors use special scans to track it. This is an early step toward better imaging for these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radiolabeled compound called IR199, tagged with gallium-68 or iodine-131, given as a single dose
What this could lead to
If successful, this could help doctors better detect and monitor Claudin 18.2-positive gastric and pancreatic cancers using imaging.
What could go wrong
This is a very early, small study with only 10 participants, so results may not apply broadly. The compound's safety and effectiveness for imaging are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER PANCREATIC CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.